Adial Pharmaceuticals
NASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Guardion Health Sciences
NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Heat Biologics
NASDAQ:HTBXHeat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Novelion Therapeutics
NASDAQ:NVLNNovelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Tocagen
NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.